Tag: Valneva
Valneva: welcome news
By Jean-Baptiste André Published on 03/18/2024 at 11:55 a.m. Photo credit © Valneva (Boursier.com) — Valneva climbs…
Valneva: the stock falls, forecasts below expectations
(CercleFinance.com) – Valneva retreats on the Paris Stock Exchange on Wednesday morning after revealing annual revenue forecasts below market expectations. The vaccine specialist has raised its sales forecasts for 2024,…
Valneva: raising its sales forecasts in 2024 – 03/20/2024 at 08:59
(AOF) – Valneva published a turnover for its 2023 financial year of 153.7 million euros including 144.6 million euros in product sales. Product sales are 12% higher than those preceding…
Valneva postpones the start of repayment of the loan contracted with Deerfield and Orbimed – 03/18/2024 at 07:09
Valneva SE VLS.PA: * ANNOUNCES A POSTPONEMENT OF THE START DATE OF REPAYMENT OF THE LOAN CONTRACTED WITH THE DEERFIELD AND ORBIMED COMPANIES * DELAYS THE START DATE OF YOUR…
Valneva: erases the resistance of 3.545E
(CercleFinance.com) – Valneva regains +5% and erases the resistance of 3.545E (ex-floor of February 2) and should soon face the resistance of 3.775E of February 8.In the event of a…
Valneva: postponement of the first repayment of a loan
(CercleFinance.com) – Valneva recorded clear progress on Monday morning on the Paris Stock Exchange despite the announcement of the postponement of the repayment of a loan taken out in 2020…
Valneva: the Grimaud family group less than 15% of the votes – 03/05/2024 at 1:10 p.m.
Member Login Customer Login (CercleFinance.com) – The Grimaud family group declared to the AMF that it had crossed the threshold of 15% of Valneva’s voting rights on March 4, to…
Valneva: the Grimaud family group crosses a new declining threshold
LR source AMFPublished on 05/03/2024 at 09:40 a.m.Updated 03/05/2024 at 9:43 a.m. Photo credit © Valneva (Boursier.com) — The Grimaud family…
Valneva: the chikungunya vaccine recommended in the United States
(AOF) – Valneva today announced that the Advisory Committee on Immunization (Acip) of the United States Centers for Disease Control and Prevention (CDC) recommends the use of its single-shot chikungunya…
Valneva: what potential?
(Boursier.com) — Valneva fell 1% to 3.77 euros this Friday in Paris, while the company specializing in vaccines announced its turnover and cash flow for the 2023 financial year and…
Valneva expects an increase in sales in 2024 thanks to the chikungunya vaccine – 02/15/2024 at 11:51
(AFP/JUSTIN TALLIS) The Franco-Austrian pharmaceutical group Valneva is counting on an increase in its sales for 2024, notably with the marketing of its vaccine against chikungunya, Ixchiq, approved in the…
Valneva: transfer of the priority review voucher for Ixchiq – 02/05/2024 at 08:00
(CercleFinance.com) – Valneva announces the sale for 103 million dollars (95 million euros) of the priority review voucher that it obtained from the American FDA, for its single injection vaccine…